The median survival rate of ALS patients in the high M50 group was more than twice as high as in the low M50 group, which implicates a worser outcome in patients with higher LMN loss and could be a promising prognostic marker. The gene discussed is LMNB1; the disease is amyotrophic lateral sclerosis.